Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Agder and Normet Agree on Service Partnership for Norway

Espoo & Kristiansand, September 4th 2020, Normet and Agder have signed an agreement making Agder as a service provider for Normet services in Norwegian market. Agder will be responsible for providing on-site and field service for customers and doing repairs and maintenance of Normet fleet in Norway. Agder will also maintain a stock of spare parts to ensure a high-quality customer service.  The agreement is effective from September 1st. The agreement enhances co-operation between Agder and Normet  “Agder has a wide coverage with customers and plenty of fleet with Norwegian tunnel

New investment analysis of OssDsign and upcoming presentation

Swedish investment bank Redeye has initiated coverage of OssDsign and today published an initial analysis report. OssDsign has also been included on Redeye’s “Conviction Buy List”. On Monday 7 September, OssDsign’s new CEO Morten Henneveld will present the company during the ABG Sundal Collier Investor Day. The presentation starts 14.30 CET and will stream live here: https://www.introduce.se/artiklar/2020/9/abgsc-investor-day-livestreamed-seminar-7-September/ The Redeye analysis can be found here: https://www.redeye.se/research/792865/ossdsign-growth-set-to-accelerate   For

Hamlet Pharma regains patent rights for BAMLET

The board of Hamlet Pharma has decided to accept a proposal from Linnane Pharma to terminate the patent license agreement from May 12, 2020.Hamlet Pharma AB and Linnane Pharma AB entered into a licensing agreement on 12 May 2020, for the development of BAMLET; a complex formed by bovine alpha-lactalbumin and oleic acid. According to the agreement, Linnane Pharma would under Hamlet Pharma's patents develop the product BAMLET for non-pharmaceutical use. Since then, Linnane Pharma has worked intensively to drive the project forward. However, the board of Linnane Pharma has acknowledged

Fabege is included in the sustainability index Global Challenges (GCX)

Fabege is the first real estate company to qualify for GCX. The fact that all investment properties are environmentally certified according to BREEAM In-Use and all new production is certified according to BREEAM-SE is the reason for the inclusion in the index.GCX comprises 50 international shares in companies that make pioneering contributions to tackling global challenges such as climate change, ensuring access to clean drinking water, deforestation, biodiversity, population development, poverty and global governance.The value of products and certificates based on the Global Challenges

European Action Plan on Critical Raw Materials and Launch of European Raw Materials Alliance

Vancouver, September 4, 2020 /CNW/ – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) welcomes the launch of a European Raw Materials Alliance (“ERMA”) which was announced by the European Commission as part of an Action Plan on Critical Raw Materials [1]. The Action Plan on Critical Raw Materials is aimed to develop resilient value chains for European Union (“EU”) industrial ecosystems, reduce dependency on primary critical raw materials, strengthen domestic sourcing of raw materials in the EU, and diversify

RhoVac appoints Professor Georg Holländer to its Scientific Advisory Board

RhoVac AB ("RhoVac") announces today September 4[th] 2020,  that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Holländer, Action Research Professor and Head of Department at Oxford University, UK  and Professor in Development Immunology, ETH Zurich, Switzerland, and Pediatric Immunology, University of Basel, Switzerland to the Scientific Advisory Board. Professor Holländer is also Director of the Botnar Research Center for Child Health (BRCCH) in Basel, Switzerland.Professor Georg Holländer, MD, PhD, joins RhoVac

Lehto Group Plc: Notice to the Extraordinary General Meeting 25 September 2020 of Lehto Group Plc

Lehto Group PlcNotice to the Extraordinary General Meeting4 September 2020 at 12.00 (EET)The shareholders of Lehto Group Plc are hereby invited to the Extraordinary General Meeting held on Friday 25th September 2020 at 2 pm in Kempele, in Lehto Group Plc’s headquarters (Voimatie 6, Kempele). Doors open at 1:30 pm for the reception and distribution of the voting tickets. A. Agenda of the Extraordinary General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of the persons to scrutinise the minutes and to supervise the counting of votes 4.

Composition of Kojamo plc’s Nomination Board

Kojamo plc Stock Exchange Release, 4 September 2020 at 12:00 noon EESTComposition of Kojamo plc’s Nomination Board Kojamo plc’s three largest shareholders have nominated the following members to the Shareholders’ Nomination Board: · Jouko Pölönen, CEO, Ilmarinen Mutual Pension Insurance Company · Risto Murto, CEO, Varma Mutual Pension Insurance Company · Riku Aalto, President, The Finnish Industrial Union In addition, Chairman of Kojamo’s Board of Directors, will serve as the Nomination Board’s expert member. The right to nominate representatives is vested with the three

EXTRAORDINARY GENERAL MEETING OTELLO CORPORATION ASA

At the request of Sand Grove, an extraordinary general meeting was held today. Sand Grove's proposals did not attract the required majority and none of the proposals were thus approved. The minutes from the meeting are attached hereto.Petter Lade, CFO Phone: +47 91143878 E-mail: petterl@otellocorp.com   About Otello: Otello holds shares in several different businesses, including (i) AdColony which helps publishers monetize their content through advertising and advertisers reach the audiences that build value for their businesses, capitalizing on a global consumer

Observe Medical ASA: Registration of share capital increase following exercise of employee share options

Oslo, 4 September 2020: Reference is made to the stock exchange announcement by Observe Medical ASA (the "Company") on 31 August 2020 regarding the exercise of employee share options and issue of 171,875 new shares in the Company. The NOK 44,687.50 share capital increase pertaining to the exercise of the employee share options has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 5,097,418.82 divided into 19,605,457 shares, each with a par value of NOK 0.26. For further information, please contact: Björn Larsson, CEO,

Södra to raise price of NBSK by USD 40 to USD 880/tonne

Södra Cell is increasing the price of its northern bleached softwood kraft (NBSK) pulp in Europe by $40/tonne to $880, effective 1 October.“We do recognize the challenges presented in the wake of Covid-19. Nevertheless, demand for our NBSK in Europe has stayed healthy over the summer, and lately we’ve seen distinct signs of China recovering. Our stocks are balanced, and as we head into a period where numerous global maintenance stops will restrict supply, we expect the overall supply chain to tighten up. Current net price of NBSK in Europe is not sustainable and an upward momentum on price

GLASTON CORPORATION: RESOLUTIONS OF THE EXTRAORDINARY GENERAL MEETING

Glaston Corporation      Stock Exchange Release 4 September 2020 at 10.30 a.m.The Extraordinary General Meeting of Glaston Corporation was held on 4 September 2020 in Helsinki. Composition of the Board of DirectorsIn accordance with the proposal of the Shareholders’ Nomination Board, the number of the members of the Board of Directors was resolved to be eight. The Extraordinary General Meeting decided, in accordance with the proposal of the Shareholders’ Nomination Board, to elect Mr. Veli-Matti Reinikkala as a new member of the Board of Directors, in addition to the current members of

Listing prospectus for Finnair's EUR 200 million capital securities available; listing application submitted

Finnair Plc                   Stock Exchange Release                  4 September 2020 at 10.30 a.m. EEST NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Finnair Plc (the “Company”) announced on 27 August 2020 its decision to issue a hybrid bond of EUR 200 million (the “Hybrid Bond”). The Hybrid Bond was issued on 3 September 2020. The Finnish

Oncoinvent Advances Radspherin[®] to Second Dose Level in Ongoing Phase 1 Clinical Trial

Safety review of first dose-level cohort allows progression to second cohort of colorectal cancer patients with peritoneal carcinomatosis in Radspherin[®] clinical trial.Oslo 4. September 2020  Oncoinvent AS, a clinical stage radiopharmaceutical company developing novel radioisotope-based therapies announced today that the trial Safety Monitoring Committee overseeing the first-in-human Phase 1 clinical study of Radspherin[®] in colorectal cancer patients suffering from peritoneal carcinomatosis have approved the advancement of the study to the second level dosing cohort. Jan A.

Improved market conditions for pyrolysis oil could strongly increase revenues from Enviro’s plants

Over the past year, Scandinavian Enviro Systems AB (publ, “Enviro” or “the Company”) has noticed a dramatic increase in interest in the oil—known as pyrolysis oil—that the company can extract from end-of-life tyres using its proprietary technology. The oil has a high bio content due to the natural rubber in tyres, and in the company’s opinion is therefore of great interest to many players in the market because it could replace fossil-based alternatives. “Based on the market response and our own calculations, we judge that the oil recovered from end-of-life tyres could contribute to a

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

Announcement no. 35 - 4 September 2020 In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, Motortramp A/S continuously sells shares pro rata and the market is to be informed accordingly – see the attached file. Kind regards, Dampskibsselskabet NORDEN A/S Martin Badsted CFO For further information: Martin Badsted, CFO, tel.: +45 3315 0451Anne-Louise Dam-Rasmussen, Head of Communications, tel.: +45 3273 0624

Paulig intends to make a 45-million EUR investment in the Tex Mex production in Belgium

Paulig aims to strengthen its position as a market leader of Tex Mex in Europe with a 45-million EUR investment into a new production facility in Roeselare, Belgium. The new factory, which would be built next to the existing facilities, will focus on producing tortillas and increase the company’s innovation capabilities. Paulig expects to start production in the new factory in spring 2022. “This investment marks an important step in the execution of our international growth strategy. It is the biggest investment Paulig has made outside Finland and will strengthen our leading

Karin Hedlund new Head of IT at Axfood

Karin Hedlund will be the new Head of IT at Axfood with responsibility for the Axfood Group’s IT operations and strategy as well as the company’s extensive IT development plan.Most recently, Karin Hedlund served as Head of IT (CIO) at Lantmännen for more than seven years. Prior to her role at Lantmännen, she held leading positions at Ericsson and Accenture with a focus on IT and business development within the food retail sector and telecom, as well as different board positions. Karin is familiar with Axfood as she during seven years after the turn of the millennium was development manager

Risk Intelligence A/S appoints new Chief Commercial Officer, as part of the future-facing commercial organisation

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces today that the company has appointed the current Sales Director Jim Pascoe as new Chief Commercial Officer to head the new commercial organisation.As part of a new commercial plan that optimises the organisation, Risk Intelligence has promoted Sales Director Jim Pascoe as new Chief Commercial Officer. In this position, Jim Pascoe gets the full responsibility to re-configure, optimise, and invigorate the commercial side in the Company including sales and marketing, client relations and retention.   Building on the

BioStock: CombiGene gears up in epilepsy project

Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy.Read the full article about CombiGene at biostock.se: https://www.biostock.se/en/combigene-gears-up-in-epilepsy-project/ This is a press release from BioStock -

US ARMY 2nd SFAB expands capability with new portable Intercom system from INVISIO

The US Army 2nd Security Force Assistance Brigade (SFAB) will add the new lightweight and portable Intercom system from INVISIO to their capabilities to enable instant deployment into any military or commercial passenger vehicle or platform. Following testing the SFAB has now placed an initial order for delivery in the second half of 2020. The order value does not exceed SEK 5 million. INVISIO’s Intercom system will provide the US Army 2nd Security Force Assistance Brigade with seamless integration of all communication sources such as radios or devices, as well as a unique inter-team

Alligator Bioscience presents positive biomarker data demonstrating proof of mechanism in mitazalimab clinical Phase I study

Lund, Sweden, September 4, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer. The data will be presented today at the scientific conference PEGS: The Essential Protein Engineering Summit being held virtually August 31- September 4, 2020. “The presented biomarker data confirm the proof of mechanism and strengthen our belief in mitazalimab as a powerful therapeutic agent. The

Members of the Shareholders' Nomination Board of Tikkurila

Tikkurila Oyj, Stock Exchange Release, 4 September 2020 at 9:30 a.m. (EEST) Members of the Shareholders' Nomination Board of Tikkurila The Shareholders' Nomination Board of Tikkurila Oyj has been appointed. The members of the Nomination Board are: · Annika Paasikivi, President & CEO (Oras Invest Ltd) · Hanna Kaskela, Director, Responsible investment (Varma Mutual Pension Insurance Company) · Patrick Lapveteläinen, CIO (Sampo Group), Chairman of the Board of Directors (Mandatum Life) · Expert member of the Nomination Board: Jari Paasikivi, Chairman of the Board of

BioStock: Cyxone is looking forward to an eventful autumn

When Tara Heitner came in as new CEO for the Malmö-based biotech company Cyxone, it marked the start of an increase in activity within the company. Shortly after she took office in June, they announced filing of new patents, recruited new scientific advisors, a head of development and established a new collaboration within a new therapeutic area. The news got the share price increasing by more than 40 per cent during summer and has ignited expectations on further value enhancing events to come.Read the full article about Cyxone at biostock.se: https://www.biostock.se/2020/09/cyxone-ser-

There are no items matching the current filter
There are no more items matching the current filter
Back to top